论文部分内容阅读
目的:研究高血压脑出血早期患者在治疗过程中采用灯盏细辛注射液的临床效果。方法:选择高血压脑出血患者59例,随机分成对照组和观察组。对照组采用常规内科治疗,即控制血压,脱水,降颅内压,保持水,电解质平衡,对症治疗,保持呼吸道通畅。观察组在采用常规内科治疗基础上,加用灯盏细辛注射液20ml,加入生理盐水250ml,静脉滴注,每天1次,14天为一个疗程。评估治疗前后神经功能缺损评分和血肿体积变化,并进行统计学分析。结果:两组患者经过治疗后,神经功能和血肿体积明显得到改善,观察组的改善程度更加明显,p<0.05差异有统计学意义。结论:对高血压脑出血早期患者使用灯盏细辛注射液治疗安全有效,值得临床推广。
Objective: To study the clinical effect of using Dengzhanxixin injection in the early stage of hypertensive intracerebral hemorrhage. Methods: 59 patients with hypertensive cerebral hemorrhage were randomly divided into control group and observation group. Control group using conventional medical treatment, that control blood pressure, dehydration, decreased intracranial pressure, maintain water, electrolyte balance, symptomatic treatment, to maintain airway patency. Observation group in the use of conventional medical treatment based on the addition of Erigeron Injection 20ml, added 250ml of saline, intravenous infusion, once daily, 14 days for a course of treatment. Assessment of neurological deficit scores and hematoma volume changes before and after treatment, and statistical analysis. Results: After treatment, the neurological function and hematoma volume of two groups of patients were significantly improved, and the improvement degree of the observation group was more obvious. The difference was statistically significant at p <0.05. Conclusion: It is safe and effective to use Erigeron Breviscapus Injection in the early stage of hypertensive intracerebral hemorrhage.